Milestone Pharmaceuticals lands $55 mln Series C
Montreal-based Milestone Pharmaceuticals Inc, a clinical stage cardiovascular company, has closed $55 million in Series C financing. Novo Holdings A/S led the round with participation from other investors that included Forbion Capital Partners, Tekla Capital Management, Domain Associates, Fonds de solidarité FTQ, BDC Capital, Pappas Capital and GO Capital. In conjunction with this financing, Dr. Nilesh Kumar of Novo Ventures US Inc has been added to Milestone's board of directors while Daniel Omstead of Tekla Capital Management will become an board observer.
1 August 2017•1 min read
